Financial News

Forest Laboratories, Inc. (NYSE: FRX), an international manufacturer and marketer of pharmaceutical products, will release its Fiscal 2013 Fourth Quarter financial results before the U.S. stock market opens on Tuesday, April 23, 2013. At 10:00 AM EDT, Forest will host a conference call where Elaine Hochberg, Executive Vice President, Sales & Marketing and Chief Commercial Officer, Frank Perier, Executive Vice President Finance & more...

Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical manufacturer and marketer, today reported a GAAP loss per share of $0.58 in the third quarter of fiscal 2013 compared with income of $1.04 in the third quarter of fiscal 2012. Included in the third quarter results were upfront/licensing agreement payments totaling $76.0 million, or $0.29 per share, net of tax. The non-GAAP loss per share was $0.21 in the third fiscal quarter more...

Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical company, and Adamas Pharmaceuticals, Inc. announced today that they have entered into an agreement for the development and commercialization of a fixed dosed combination (FDC) of Namenda XR® (memantine HCl extended release) and donepezil HCl as a once daily therapy for the treatment of moderate to severe dementia of the Alzheimer’s type in the United States.

Forest Laboratories, Inc. (NYSE: FRX), an international manufacturer and marketer of pharmaceutical products, will release its Fiscal 2013 Second Quarter financial results before the U.S. stock market opens on Tuesday, October 16, 2012. At 10:00 AM EDT, Forest will host a conference call where Elaine Hochberg, Executive Vice President, Sales & Marketing and Chief Commercial Officer, Frank Perier, Executive Vice President Finance & more...

Howard Solomon, Chairman, Chief Executive Officer and President of Forest Laboratories, Inc. (NYSE: FRX), today sent the following letter to Carl C. Icahn:

July 9, 2012

Via Federal Express

Forest Laboratories, Inc. (NYSE: FRX), an international manufacturer and marketer of pharmaceutical products, will release its Fiscal 2013 First Quarter financial results before the U.S. stock market opens on Tuesday, July 17, 2012. At 10:00 AM EDT, Forest will host a conference call where Elaine Hochberg, Executive Vice President, Sales & Marketing and Chief Commercial Officer, Frank Perier, Executive Vice President Finance & more...

Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical manufacturer and marketer, today announced that reported earnings per share equaled $0.72 in the fourth quarter of fiscal 2012. Reported earnings per share in the fourth quarter of fiscal 2011 were $1.12. Excluding acquisition related amortization, non-GAAP EPS in the fourth fiscal quarter of 2012 equaled $0.78 as compared with $1.14 in the fourth quarter of fiscal 2011. more...

NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical manufacturer and marketer, today announced that reported earnings per share were $1.04 in the third quarter of fiscal 2012.

NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical manufacturer and marketer, today announced that reported earnings per share equaled $0.91 in the second quarter of fiscal 2012. Reported earnings per share in the second quarter of fiscal 2011 were $1.00.

NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) announced today that it has entered into an agreement with Morgan Stanley & Co. Incorporated to repurchase an additional $350 million of its common shares under an accelerated share repurchase program. Forest will acquire these common shares under the Board authorized fifty million share repurchase program announced on May 18, 2010.

NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical manufacturer and marketer, today announced that reported earnings per share equaled $0.90 in the first quarter of fiscal 2012. Excluding a charge of $40.0 million, or $0.14 per share net of tax for a new product licensing fee, non-GAAP earnings per share for the first fiscal quarter were $1.04 per share.

NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) announced today that it has entered into an agreement with Morgan Stanley & Co. Incorporated to repurchase $500 million of its common shares under an accelerated share repurchase program. Forest will acquire these common shares under the Board authorized 50 million share repurchase program announced on May 18, 2010.